Catheter-related bloodstream infection (CRBSI) - Pipeline Insight, 2024

Catheter-related bloodstream infection (CRBSI) - Pipeline Insight, 2024

DelveInsight’s, “Catheter-related Bloodstream Infection -Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Catheter-related Bloodstream Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Catheter-related Bloodstream Infection Understanding

Catheter-related Bloodstream Infection: Overview

Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravenous catheter. It is one of the most frequent, lethal, and costly complications of central venous catheterization and also the most common cause of nosocomial bacteremia. Intravascular catheters are integral to the modern practices and are inserted in critically-ill patients for the administration of fluids, blood products, medication, nutritional solutions, and for hemodynamic monitoring. Central venous catheters (CVCs) pose a greater risk of device-related infections than any other types of medical device and are major causes of morbidity and mortality. They are also the main source of bacteremia and septicemia in hospitalized patients. Majority of CRBSIs are associated with CVCs and in prospective studies, the relative risk for CRBSI is up to 64 times greater with CVCs than with peripheral venous catheters.

Symptoms

The diagnosis of Catheter-related bloodstream infection is often suspected clinically in a patient using a CVC who presents with fever or chills, unexplained hypotension, and no other localizing sign.[19,20] Mild symptoms include malaise and nausea, and severe symptoms include high fever with rigors, hypotension, vomiting, and changes in mental status in the setting of a normal catheter exit site or tunnel, on physical examination.

Diagnosis

The diagnosis of Catheter-related bloodstream infection requires a positive culture of blood from a peripheral vein and clear evidence that the catheter is the source. Catheter-related bloodstream infection can be diagnosed when colony counts are at least 3-fold higher in cultures of blood obtained via the CVC than in cultures of blood taken from a peripheral vein. If a blood sample cannot be drawn from a peripheral vein, it is recommended that 2 blood samples should be drawn through different catheter lumens, and the colony count for the blood sample drawn through one lumen is at least 3-fold greater than the colony count for the blood sample obtained from the second lumen should be considered to indicate possible CRBSI.

Treatment

Catheters should be removed from patients with Catheter-related bloodstream infection associated with any local or systemic inflammation or immune-compromised condition. Antibiotic therapy for catheter-related infection is often initiated empirically. Recurrent bacteremia after parenteral therapy is more likely to occur if that therapy is administered through a retained catheter than if the catheter is removed. Antibiotic lock therapy for CRBSI is used in conjunction with systemic antibiotic therapy and involves installing a high concentration of an antibiotic, to which the causative microbe is susceptible in the catheter lumen.

Catheter-related Bloodstream Infection Emerging Drugs Chapters

This segment of the Catheter-related Bloodstream Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Catheter-related Bloodstream Infection Emerging Drugs

• Mino-Lok: Leonard-Meron Biosciences, Inc.

Leonard-Meron Biosciences, Inc. is conducting a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution as an adjuctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI).

Further product details are provided in the report……..

Catheter-related Bloodstream Infection: Therapeutic Assessment

This segment of the report provides insights about the different Catheter-related Bloodstream Infection drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Catheter-related Bloodstream Infection

There are approx. 5+ key companies which are developing the therapies for Catheter-related Bloodstream Infection. The companies which have their Catheter-related Bloodstream Infection drug candidates in the most advanced stage, i.e. phase III include, Leonard-Meron Biosciences, Inc. and others.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Catheter-related Bloodstream Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as:

• Small molecules
• Proteins and Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Catheter-related Bloodstream Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Catheter-related Bloodstream Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Catheter-related Bloodstream Infection drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Catheter-related Bloodstream Infection R&D. The therapies under development are focused on novel approaches to treat/improve Catheter-related Bloodstream Infection.
• June 2020: New therapy reduces chronic low back pain in large international study

A new study has found that tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide. Researchers are increasingly finding that certain proteins circulating in the bloodstream heighten the sensitivity of cells in the nervous system to pain. One of these proteins, called nerve growth factor (NGF), may explain why some individuals experience more intense and chronic back pain. Tanezumab is an NGF inhibitor.

• June 2020: Relievant Announces Publication of 5-Year Data Demonstrating Long Term Clinical Benefits of the Intracept Procedure in Chronic Low Back Pain Patients

Relievant Medsystems announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intracept procedure. The recently published long-term studyi is a single-arm, open-label, prospective follow-up of 100 US patients (85% retention) who were successfully treated with basivertebral nerve ablation in the SMART randomized study. Mean patient follow-up was 6.4 years post-procedure (range: 5.4 - 7.8 years). The study evaluated functional impact using the Oswestry Disability Index (ODI), low back pain scores using a Visual Analog Scale (VAS), pain interventions post-BVN ablation, and patient satisfaction.

Catheter-related Bloodstream Infection Report Insights

• Catheter-related Bloodstream Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Catheter-related Bloodstream Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Catheter-related Bloodstream Infection drugs?
• How many Catheter-related Bloodstream Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Catheter-related Bloodstream Infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Catheter-related Bloodstream Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Catheter-related Bloodstream Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Leonard-Meron Biosciences, Inc.

Key Products

• Mino-Lok